陶积累及其在阿尔茨海默氏病频谱中的空间进展
Frédéric St-Onge1,2, Marianne Chapleau3, John Cs Breitner2,4
1Integrated Program in Neuroscience, Faculty of medicine, McGill University, Montreal, Qc, H3A 2B4, Canada.
medRxiv : the preprint server for health sciences
|June 19, 2023
概括
阿尔茨海默病的传播显示出显著的个体差异,特别是在轻度认知障碍 (MCI) 中. 了解这种空间异质性是跟踪疾病进展和认知衰退的关键.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 传统上,阿尔茨海默氏症 (AD) 病理的传播与布拉克分期有关.
- 新兴的活体正子发射断层扫描 (PET) 数据揭示了AD中异质的tau传播模式.
- 了解跨临床前和临床AD阶段的tau分布对于认知衰退的关联至关重要.
结论:
- 在阿尔茨海默病的所有临床阶段中,沉积存在显著的个体异质性,尽管普遍遵循布拉克分期.
- 病理的空间进展在轻度认知障碍的个体中最快.
- 进一步探索全脑分布可能会揭示与超越记忆缺陷的各种认知障碍相关的病理变异.
相关概念视频
01:26Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
01:22Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223